GMAB vs ONC
Genmab A/S and BeOne Medicines AG, both Healthcare
BeOne Medicines AG is the larger company at $46B against $33B. Over the past year GMAB returned +75% against +23% for ONC.
| Figure | GMAB | Both figures drawn to one scale | ONC |
|---|---|---|---|
| Last close | $50.98 | $404 | |
| Market cap | $33B | $46B | |
| Trailing P/Eshare price over earnings per share | 33.2 | n/a | |
| Revenue growthlast twelve months on the year before | +19% | n/a | |
| Operating margin | 29% | n/a | |
| Net margin | 26% | n/a | |
| Free cash flow yield | 3.5% | n/a | |
| Net cashcash minus all debt | $3.6B net debt | n/a | |
| Insiders, 12 monthsopen-market Form 4 trades | n/a | sold $392M net | |
| 1-year return | +75% | +23% | |
| 5-year return | +9.6% | +8.0% |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher number in each row, nothing more.
Genmab A/S
Revenue of $2.1B in the quarter to Dec 31, 2025, net income $432M.
BeOne Medicines AG
Open these two in the interactive comparison to add more names, change the period or see the correlation.